FDA Panel Fails to Support Novel Opioid for Depression

Share this post

An FDA advisory panel failed to endorse the approval of a novel opioid to treat major depressive disorder because of insufficient efficacy data.
News Alerts

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply